CA-PULSESG
20.10.2021 15:02:13 CEST | Business Wire | Press release
pulsESG™ today announced the launch of its enterprise environmental, social, and governance (ESG) software as a service (SaaS) platform backed by $8.5 million in seed funding from leading impact-driven investors and led by two Silicon Valley enterprise software veterans. The platform distinguishes itself in the marketplace through features such as model-driven architecture and full integration with both internal sources of data and external investor-facing systems, empowering companies to track and derive insights for ESG compliance and improvement based on stakeholder requirements. The company emerged from stealth mode today and the product is expected to be made generally available in Q1 2022.
Led by tech veterans and co-founders Murat Sönmez and Inderjeet Singh, the pulsESG™ platform is designed to take a different approach to ESG analysis than what currently exists in the marketplace by providing comprehensive, auditable, and accurate deep analytics that can be integrated with both the source and destination ESG systems of customers. This new level of information empowers enterprises to make more informed ESG decisions using a platform that also provides end-users the flexibility to modify it based on changes in the ESG regulatory landscape and according to their stakeholder needs.
“Amidst changing impact benchmarks at national and global levels, accurate and reliable ESG analysis is moving from ‘nice-to-have’ to ‘must-have’ for enterprises worldwide, so we sought to develop a platform to help customers navigate this fluid landscape,” explained Co-founder, President, and CTO Inderjeet Singh. “The pulsESG™ platform was designed to raise the bar on quality and timeliness, allowing customers to respond to changes in the ESG models themselves, not just data points within current data models.”
“Simply put, pulsESG™ offers an integrated, comprehensive, and flexible SaaS platform for enterprises to define, capture, analyze, derive insight, and improve their ESG footprint,” added Murat Sönmez, Co-founder and CEO.
While private equity firms, their investors, and other stakeholders increasingly take ESG impacts and risk into account, the measurement tools and benchmarks for each continue to evolve—both across sectors and jurisdictions. Sönmez and Singh saw the opportunity to leverage their experience with SaaS platforms, integration, business processes, analytics, and master data management to create a system to help enterprises navigate and respond to this inherent fluidity in ESG analysis. The result of their vision is the pulsESG™ platform.
Sönmez and Singh have found early backing from leading investors in the impact-driven investment space, including FINTOP Capital, Aligned Climate Capital, SOMPO Holdings (Japan), Builders VC, eLab Ventures, and individual investors including Alberto Cribiore and André Borschberg.
Prior to co-founding pulsESG™, Murat Sönmez was a member of the founding team at TIBCO Software and led it past the billion-dollar revenue mark as the head of its customer facing operations. Sönmez later joined the Managing Board of the World Economic Forum in Switzerland, leading its global business community engagement efforts, and subsequently established and led its global technology policy network out of San Francisco.
pulsESG™ Co-founder Inderjeet Singh was most recently responsible for Oracle’s middleware and cloud platform and previously for TIBCO’s infrastructure products. Inderjeet joined TIBCO Software through the acquisition of Velosel—a leading master data management platform—where he was part of the founding team and led all product functions.
Investor Statements
“ESG reporting is quickly becoming standard practice for companies and investors worldwide. As an investor that cares deeply about ESG, we are excited about pulsESG’s ability to ensure that analysis and reporting is more real, reliable, and reportable."
— Peter W. Davidson, CEO, Aligned Climate Capital
"As one of the world’s largest economies, Japan faces pressure from an aging society with social impact and other ESG considerations steering business decisions more than ever. SOMPO has been working to address these issues in innovative ways and utilizing digital technologies to accurately measure our impact, so are excited to have found a partner in pulsESG—an integrated and comprehensive platform with the potential to accelerate SOMPO’s impact for society.”
— Kengo Sakurada, Group CEO, Director, President and Representative Executive Officer, SOMPO Holdings, Inc.
“In a crowded field of ESG platforms, Murat and Inderjeet stand apart with the completeness of their vision, passion for impact, and unparalleled combined experience in successfully scaling startups, developing mission-driven software platforms, and executing strategic engagement with top level leadership in organizations worldwide. We are pleased to lead the investment and look forward to an impactful journey together.”
— Rick Kushel, Co-founder and General Partner of FINTOP Capital
About pulsESG™
Founded in 2021, pulsESG, Inc. is a public benefit corporation dedicated to empowering purpose-driven enterprises to manage and improve their ESG footprint with an integrated and comprehensive SaaS platform built for compliance tracking and insight.
For more information: www.pulsESG.com
LinkedIn: www.linkedin.com/company/pulsESG
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005350/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom